Back to all papers

Prediction of hormone receptor status in breast cancer brain metastases using an MRI-based multimodal deep learning framework.

June 15, 2026pubmed logopapers

Authors

Sun Q,Zhang Q,Xiao Y,Pei X

Affiliations (4)

  • The Third Affiliated Hospital of Beijing University of Chinese Medicine, Beijing, China.
  • School of Clinical Medicine, Beijing University of Chinese Medicine, Beijing, China.
  • School of Electronic Engineering, Beijing University of Posts and Telecommunications, Beijing, China.
  • Xiamen Hospital of Traditional Chinese Medicine, Xiamen, China.

Abstract

Breast cancer brain metastases (BCBMs) represent a severe neurological complication affecting 10-20% of patients with metastatic breast cancer, with significant implications for treatment planning and prognosis. Accurate determination of hormone receptor (HR) status is critical for guiding personalized therapeutic strategies. However, traditional biopsy-based assessment is invasive, carries procedural risks, and may not capture the molecular heterogeneity of multiple metastatic lesions. Non-invasive methods for predicting HR status from brain MRI could transform clinical practice, yet existing approaches face three critical limitations: incomplete information utilization from single-modal features, ignored biological correlations among hormone receptors, and underexploited anatomical position information. We developed a novel multi-modal deep learning (DL) framework leveraging the BCBM-RadioGenomics dataset from The Cancer Imaging Archive (TCIA), comprising 268 MRI studies from 165 patients with expert-validated tumor segmentations, 107 PyRadiomics-derived radiomic features, and clinical HR status. Our framework introduces three key methodological components: (1) a three-modal complementary fusion architecture integrating 3D DL features extracted from tumor regions of interest using a 3D ResNet, radiomic features, and anatomical position encoding representing tumor location through hemisphere and brain region one-hot encoding; (2) a multi-task collaborative learning framework with hard parameter sharing to simultaneously predict ER, PR, and HER2 status, employing a weighted loss function to address class imbalance; and (3) a lesion-level sampling strategy to maximize data utilization while preventing data leakage. The proposed model achieved area under the curve (ROC-AUC) values of 0.8763 ± 0.0393 for HER2, 0.8621 ± 0.0304 for ER, and 0.8993 ± 0.0192 for PR prediction, outperforming traditional machine learning baselines. The multi-task learning framework demonstrated improvements for the challenging PR prediction task, while the three-modal fusion architecture consistently outperformed single-modal approaches across all tasks. This study demonstrates the feasibility and clinical potential of non-invasive molecular profiling of BCBMs using a multi-modal DL approach. These findings might offer a promising tool for treatment planning and patient management, reducing the need for invasive biopsies while enabling more accurate and comprehensive molecular characterization of brain metastases.

Topics

Journal Article

Ready to Sharpen Your Edge?

Subscribe to join 11k+ peers who rely on RadAI Slice. Get the essential weekly briefing that empowers you to navigate the future of radiology.

We respect your privacy. Unsubscribe at any time.